
GSK advances the future of respiratory medicine and patient care with new data presented at ATS
GSK to Present 43 Abstracts Across Respiratory Portfolio at ATS 2025, Including New Data on Mepolizumab and Depemokimab GSK plc (LSE/NYSE: GSK) today announced that 43 abstracts, including four late-breaking…












